GSK3B and myelofibrosis: DB08512 is an experimental compound with no clinical use reported, and Elraglusib (9-ING-41) is a GSK-3β inhibitor in trials for other malignancies (e.g., myelofibrosis) without demonstrated efficacy in AML [23,25,26].